- Home
- JAZZ vs EXLS Comparison
JAZZ vs EXLS Comparison
Compare JAZZ & EXLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JAZZ
- EXLS
- Stock Information
- Founded
- JAZZ 2003
- EXLS 1999
- Country
- JAZZ Ireland
- EXLS United States
- Employees
- JAZZ N/A
- EXLS N/A
- Industry
- JAZZ Biotechnology: Pharmaceutical Preparations
- EXLS Business Services
- Sector
- JAZZ Health Care
- EXLS Consumer Discretionary
- Exchange
- JAZZ Nasdaq
- EXLS Nasdaq
- Market Cap
- JAZZ 8.1B
- EXLS 7.9B
- IPO Year
- JAZZ 2007
- EXLS 2006
- Fundamental
- Price
- JAZZ $136.01
- EXLS $48.00
- Analyst Decision
- JAZZ Strong Buy
- EXLS Strong Buy
- Analyst Count
- JAZZ 14
- EXLS 8
- Target Price
- JAZZ $177.50
- EXLS $44.13
- AVG Volume (30 Days)
- JAZZ 688.4K
- EXLS 821.1K
- Earning Date
- JAZZ 02-25-2025
- EXLS 02-25-2025
- Dividend Yield
- JAZZ N/A
- EXLS N/A
- EPS Growth
- JAZZ 458.10
- EXLS 8.50
- EPS
- JAZZ 7.04
- EXLS 1.14
- Revenue
- JAZZ $3,992,712,000.00
- EXLS $1,771,004,000.00
- Revenue This Year
- JAZZ $7.53
- EXLS $14.68
- Revenue Next Year
- JAZZ $6.94
- EXLS $12.30
- P/E Ratio
- JAZZ $19.42
- EXLS $42.28
- Revenue Growth
- JAZZ 5.23
- EXLS 11.29
- 52 Week Low
- JAZZ $99.06
- EXLS $28.16
- 52 Week High
- JAZZ $138.27
- EXLS $52.43
- Technical
- Relative Strength Index (RSI)
- JAZZ 68.46
- EXLS 40.05
- Support Level
- JAZZ $134.56
- EXLS $50.05
- Resistance Level
- JAZZ $138.27
- EXLS $52.07
- Average True Range (ATR)
- JAZZ 3.56
- EXLS 1.25
- MACD
- JAZZ 1.17
- EXLS -0.41
- Stochastic Oscillator
- JAZZ 88.20
- EXLS 2.42
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About EXLS ExlService Holdings Inc.
ExlService Holdings Inc. is a business process management company that provides digital operations and analytical services to clients driving enterprise-scale business transformation initiatives that leverage company's deep expertise in analytics, AI, ML and cloud. The company offers business process outsourcing and automation services, and data-driven insights to customers across multiple industries. The company operates through four segments based on the products and services offered and markets served: Insurance, Healthcare, Emerging, Analytics. The vast majority of the company's revenue is earned in the United States, and more than half of its revenue comes from Analytics segment.